Cheishvili D, Stefanska B, Yi C, Li C, Yu P, Arakelian A
Oncotarget. 2015; 6(32):33253-68.
PMID: 26427334
PMC: 4741763.
DOI: 10.18632/oncotarget.5291.
Zhang Y, Zhao D, Gong C, Zhang F, He J, Zhang W
World J Surg Oncol. 2015; 13:208.
PMID: 26108802
PMC: 4511445.
DOI: 10.1186/s12957-015-0619-1.
Ma G, Liu Y, Gao H, Miao Q, Luo T, Zeng X
Dig Dis Sci. 2013; 59(2):328-35.
PMID: 24185685
DOI: 10.1007/s10620-013-2925-1.
Zhang W, Tan W, Wu X, Poustovoitov M, Strasner A, Li W
Cancer Cell. 2013; 23(5):647-59.
PMID: 23602409
PMC: 3981467.
DOI: 10.1016/j.ccr.2013.03.012.
Kawaguchi J, Adachi S, Yasuda I, Yamauchi T, Nakashima M, Ohno T
Mol Cancer. 2012; 11:45.
PMID: 22788833
PMC: 3477093.
DOI: 10.1186/1476-4598-11-45.
Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.
Sinn H, Elsawaf Z, Helmchen B, Aulmann S
Breast Care (Basel). 2012; 5(4):218-226.
PMID: 22590441
PMC: 3346166.
DOI: 10.1159/000319624.
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
Belkhiri A, Dar A, Peng D, Razvi M, Rinehart C, Arteaga C
Clin Cancer Res. 2008; 14(14):4564-71.
PMID: 18579663
PMC: 2842884.
DOI: 10.1158/1078-0432.CCR-08-0121.
Aspects of molecular phenotype and its correlations with breast cancer behaviour and taxonomy.
Hanby A
Br J Cancer. 2005; 92(4):613-7.
PMID: 15700031
PMC: 2361874.
DOI: 10.1038/sj.bjc.6602421.
p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.
Tsuda H, Iwaya K, Fukutomi T, Hirohashi S
Jpn J Cancer Res. 1993; 84(4):394-401.
PMID: 8099903
PMC: 5919306.
DOI: 10.1111/j.1349-7006.1993.tb00149.x.
Detection of c-erbB-2 gene amplification in nipple discharge by means of polymerase chain reaction.
Motomura K, Koyama H, Noguchi S, Inaji H, Azuma C
Breast Cancer Res Treat. 1995; 33(1):89-92.
PMID: 7749137
DOI: 10.1007/BF00666075.
Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.
Iglehart J, Kerns B, Huper G, Marks J
Breast Cancer Res Treat. 1995; 34(3):253-63.
PMID: 7579490
DOI: 10.1007/BF00689717.
Breast cancer and a proto-oncogene.
Barnes D
BMJ. 1989; 299(6707):1061-2.
PMID: 2511965
PMC: 1837980.
DOI: 10.1136/bmj.299.6707.1061.
Transgenic oncogene mice. Tumor phenotype predicts genotype.
Cardiff R, Sinn E, Muller W, Leder P
Am J Pathol. 1991; 139(3):495-501.
PMID: 1887859
PMC: 1886229.
Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
Poller D, Galea M, Pearson D, Bell J, Gullick W, Elston C
Breast Cancer Res Treat. 1991; 20(1):3-10.
PMID: 1687505
DOI: 10.1007/BF01833351.
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.
Epstein R, Druker B, Roberts T, Stiles C
Proc Natl Acad Sci U S A. 1992; 89(21):10435-9.
PMID: 1359539
PMC: 50353.
DOI: 10.1073/pnas.89.21.10435.
Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.
Lampe B, Genz T, Maassen V, Mikorey S, Klosterhalfen T
Arch Gynecol Obstet. 1992; 251(1):45-50.
PMID: 1347986
DOI: 10.1007/BF02718277.
Overexpression of multiple oncogenes related to histological grade of astrocytic glioma.
Orian J, Vasilopoulos K, Yoshida S, Kaye A, Chow C, Gonzales M
Br J Cancer. 1992; 66(1):106-12.
PMID: 1322154
PMC: 1977917.
DOI: 10.1038/bjc.1992.225.
